Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
“Alzheimer’s disease of the heart” is a colloquial term researchers and cardiologists use to describe cardiac amyloidosis, a progressive condition where abnormal amyloid proteins accumulate in heart tissue and impair its function. Just as Alzheimer’s disease involves the buildup of misfolded proteins in the brain that damage neurons and cause cognitive decline, cardiac amyloidosis involves similar protein accumulation in the heart that disrupts the organ’s ability to pump blood effectively. The comparison highlights a critical connection: both conditions reflect the body’s failure to properly manage or clear abnormal proteins, leading to tissue damage and organ dysfunction that worsens over time. This term has gained prominence in recent years as researchers recognized that cardiac amyloidosis shares more with neurodegenerative diseases than previously understood.
The most common form, transthyretin (TTR) amyloidosis, can be either inherited or acquired, and increasingly, physicians are screening heart failure patients for amyloidosis because many cases have been missed or misdiagnosed. For families managing dementia and neurological disease, understanding this cardiac connection matters because patients with brain health concerns may also be at risk for this heart condition, and undiagnosed cardiac amyloidosis can complicate overall health management and caregiving. The parallel isn’t merely poetic—it reflects fundamental biology. Both Alzheimer’s disease and cardiac amyloidosis involve aberrant protein misfolding, accumulation despite the body’s clearance mechanisms, and progressive tissue damage that impairs organ function. This similarity has prompted researchers to investigate whether treatment approaches that work for one condition might help with the other.
Table of Contents
- Why Do Researchers Compare Heart Amyloidosis to Alzheimer’s Disease?
- How Amyloid Proteins Damage the Heart and What It Means for Overall Health
- The Inherited Form: Familial TTR Amyloidosis and Genetic Risk
- How Modern Testing and Treatments Are Changing the Prognosis
- Why Cardiac Amyloidosis Is Often Missed and the Dangers of Delay
- The Connection Between Heart Failure and Cognitive Decline
- Future Directions and Emerging Research
- Conclusion
Why Do Researchers Compare Heart Amyloidosis to Alzheimer’s Disease?
The comparison rests on striking biological similarities. In Alzheimer’s disease, amyloid-beta and tau proteins accumulate in the brain, forming plaques and tangles that kill neurons and cause irreversible cognitive decline. In cardiac amyloidosis, amyloid proteins—most commonly misfolded transthyretin (TTR)—accumulate in the heart muscle, stiffening the tissue and preventing normal contraction. Both conditions involve the body’s failure to recognize and clear misfolded proteins, allowing them to pile up and cause progressive damage.
Researchers also use this comparison because cardiac amyloidosis, like Alzheimer’s, is often asymptomatic or produces vague symptoms in early stages, meaning it may progress silently for years before diagnosis. A patient might experience subtle heart palpitations or fatigue attributed to aging, weight gain, or other conditions, while the heart is actually being infiltrated by amyloid. Similarly, early cognitive changes might be dismissed as normal aging until they become severe. The “Alzheimer’s disease of the heart” framing emphasizes this dangerous invisibility: by the time symptoms are obvious, significant damage has already occurred.
How Amyloid Proteins Damage the Heart and What It Means for Overall Health
Amyloid protein accumulation in the heart creates a stiffened muscle that can’t relax properly between beats, a condition called restrictive cardiomyopathy. As amyloid infiltrates the tissue, the heart becomes increasingly rigid and inefficient, unable to fill with blood normally or pump effectively. Over time, this leads to heart failure—the heart simply can’t do its job. For an aging person or someone with existing health concerns, this is particularly dangerous because the heart’s reduced output affects every organ, including the brain. The broader health implications are substantial.
A failing heart means reduced blood flow to the brain, which can worsen existing dementia or contribute to cognitive decline in someone who didn’t previously have neurological problems. For caregivers managing someone with Alzheimer’s disease or another dementia, undiagnosed cardiac amyloidosis can complicate care dramatically—the person may experience increased confusion, fatigue, and functional decline that seems to accelerate beyond typical disease progression. This creates a critical limitation: cardiac amyloidosis can be present and worsening while symptoms get blamed on the neurological condition alone, delaying crucial cardiac treatment. One important warning: not all heart failure is amyloidosis, but amyloidosis is underdiagnosed. Many older adults with heart failure have been assumed to have the more common forms (like ischemic cardiomyopathy from prior heart attacks), when they actually have amyloidosis. This misdiagnosis matters because treatments differ, and the newer therapies for TTR amyloidosis can slow or stabilize the condition if caught.
The Inherited Form: Familial TTR Amyloidosis and Genetic Risk
Hereditary transthyretin (TTR) amyloidosis occurs when a person inherits a mutated TTR gene that produces abnormal transthyretin protein. Unlike the sporadic (wild-type) form that develops in some older adults, familial TTR amyloidosis can strike in middle age or earlier and is highly penetrant—meaning that people who carry the mutation have a very high likelihood of developing the disease. For families with a known history of hereditary TTR amyloidosis, the concern extends beyond one person’s health; multiple family members may be at risk. The cardiac presentation in familial TTR amyloidosis often occurs alongside or ahead of neurological symptoms (peripheral neuropathy), though some patients develop only the cardiac form.
A 52-year-old man might notice progressive shortness of breath and palpitations, only to learn from genetic testing that he carries a TTR mutation and that his 48-year-old sister, previously asymptomatic, should be screened immediately. This genetic dimension adds a prevention and early detection imperative for relatives. The neurological component of familial TTR amyloidosis is important for families with dementia concerns. While the disease can cause peripheral nerve damage and, in some cases, cognitive changes through cumulative effects of poor cardiac output and reduced brain perfusion, it is not primarily a dementia disease. However, the amyloid accumulation in the nervous system can contribute to balance problems, neuropathic pain, and autonomic dysfunction that affect overall quality of life and caregiving demands.
How Modern Testing and Treatments Are Changing the Prognosis
Until recently, a diagnosis of cardiac amyloidosis meant accepting progressive heart failure with limited options. Today, several disease-modifying therapies have transformed the landscape. Tafamidis (Vyndaqel) and related medications stabilize the transthyretin protein, preventing it from misfold and aggregate further, effectively halting disease progression in many patients. When caught early, these treatments can prevent or significantly delay the need for a heart transplant, extending both lifespan and quality of life. The practical tradeoff is timing and diagnosis.
These newer drugs work best when started before extensive cardiac damage has occurred, so they demand early recognition of the condition. For someone with memory problems and a family member with known cardiac amyloidosis, cardiac screening becomes part of responsible preventive care. The drugs are expensive and require ongoing monitoring, but for patients with TTR amyloidosis, they represent the difference between stable disease and progressive heart failure requiring transplantation. Diagnostic advances matter too. Specialized cardiac imaging (cardiac MRI), newer blood biomarkers (cardiac troponins and BNP), and genetic testing have made it much easier to identify amyloidosis in patients who were previously misdiagnosed or missed entirely. A cardiologist who suspects amyloidosis can now pursue definitive diagnosis without invasive biopsy in many cases.
Why Cardiac Amyloidosis Is Often Missed and the Dangers of Delay
Cardiac amyloidosis remains underdiagnosed for several reasons. Symptoms—fatigue, shortness of breath, leg swelling, palpitations—are attributed to common conditions like hypertension, coronary artery disease, or age-related decline. On a basic echocardiogram, the heart may show thickening that looks similar to left ventricular hypertrophy from high blood pressure, and a doctor might assume that’s the cause and prescribe antihypertensive drugs, which can actually worsen amyloidosis by reducing the heart’s filling pressure. The danger of delay is severe.
By the time amyloidosis is finally diagnosed, the patient may have advanced, irreversible damage, and while newer drugs can stabilize remaining function, they cannot reverse what’s already been lost. A person misdiagnosed for five years and treated with the wrong medications is in a very different position than someone caught early. For families managing both a neurological condition and cardiovascular concerns, this missed diagnosis can complicate caregiving significantly. A critical limitation exists in screening: not all heart failure patients get screened for amyloidosis, and many primary care physicians are not yet familiar with the condition or its diagnostic criteria. If your older relative has unexplained heart failure, especially with preserved ejection fraction (the heart squeezes okay but can’t fill), amyloidosis should be on the differential diagnosis.
The Connection Between Heart Failure and Cognitive Decline
Emerging research shows that cardiac amyloidosis can contribute to cognitive problems through multiple mechanisms. Reduced cardiac output means less blood flow to the brain, which directly impairs cognitive function and may accelerate dementia in someone already vulnerable. Additionally, amyloid accumulation affects the autonomic nervous system (which regulates blood pressure and heart rate), potentially causing blood pressure drops, reduced brain perfusion, and episodes of confusion or syncope.
A 71-year-old woman with early Alzheimer’s disease is being managed with standard dementia treatments, but her cognition is declining faster than expected, and she’s increasingly fatigued. Cardiac evaluation reveals thickened heart muscle with reduced function, initially attributed to hypertension. When advanced imaging and biomarkers are obtained because her decline is atypical, cardiac amyloidosis is diagnosed. Once she starts tafamidis and cardiology follows her closely, her cardiac function stabilizes, her blood pressure regulation improves, and her cognitive decline slows—not because dementia has been reversed, but because a major contributor to her overall health deterioration has been addressed.
Future Directions and Emerging Research
Researchers are increasingly interested in whether the protein-misfolding mechanisms underlying cardiac amyloidosis and Alzheimer’s disease share therapeutic targets. If certain compounds that stabilize misfolded proteins prove beneficial in TTR amyloidosis, they might also be tested in Alzheimer’s disease research.
Additionally, better blood biomarkers for amyloid are being developed that could enable screening in primary care, identifying asymptomatic people before symptoms develop. The longer-term goal is to screen high-risk populations—older adults with unexplained heart failure, families with hereditary TTR amyloidosis, and possibly people with neurodegenerative diseases—to identify amyloidosis early and prevent progression. As awareness grows, more cases will likely be diagnosed, and the population affected by this “Alzheimer’s disease of the heart” may be larger than currently recognized.
Conclusion
“Alzheimer’s disease of the heart” is a descriptive phrase that captures a critical reality: cardiac amyloidosis and Alzheimer’s disease both involve pathological protein accumulation, progressive tissue damage, and progressive functional decline. The comparison isn’t perfect, but it has helped raise awareness of a condition that was previously underdiagnosed and untreated. For families managing dementia or neurological disease, understanding this parallel is important because cardiac amyloidosis can coexist with brain disease, complicate symptoms, and warrant separate diagnosis and treatment.
If you or a family member have unexplained heart failure, progressive fatigue with cardiac symptoms, or a family history of amyloidosis, discussing cardiac amyloidosis screening with a cardiologist is warranted. Early diagnosis and treatment with newer disease-modifying therapies can stabilize cardiac function and improve overall health, benefiting both heart and brain in the process. The comparison to Alzheimer’s disease reminds us that these are systemic diseases of aging, and that addressing one organ system can have profound effects on the health and wellbeing of the whole person.
